



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/029,413	12/20/2001	Nadia Malouf	421/29/2

25297
JENKINS & WILSON, PA
3100 TOWER BLVD
SUITE 1400
DURHAM, NC 27707

CONFIRMATION NO. 3695

FORMALITIES LETTER



OC000000007400358

Date Mailed: 01/31/2002

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

03/25/2002 BABRAHA1 00000026 10029413

FILED UNDER 37 CFR 1.53(b)

01 FC:201	370.00 OP
02 FC:205	65.00 OP
03 FC:203	378.00 OP
04 FC:202	252.00 OP

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
Applicant must submit \$ 370 to complete the basic filing fee for a small entity.
- Total additional claim fee(s) for this application is \$630.
 - \$378 for 42 total claims over 20.
 - \$252 for 6 independent claims over 3.
- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 1065.**
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at

patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

RICHARD E. JENKINS
JEFFREY L. WILSON
ARLES A. TAYLOR, JR.
DAVID P. GLOEKLER
GREGORY A. HUNT
JOHN A. LAMERDIN, Ph.D.
BENTLEY J. OLIVE
E. ERIC MILLS
JULIE A. BROADUS, Ph.D. (PATENT AGENT)



JENKINS & WILSON, P.A.

PATENT ATTORNEYS
SUITE 1400 UNIVERSITY TOWER
3100 TOWER BOULEVARD
DURHAM, NORTH CAROLINA 27707

TELEPHONE (919) 493-8000
FACSIMILE (919) 419-0383

WEBSITE
JENKINSANDWILSON.COM

RALEIGH OFFICE

NCSU CENTENNIAL CAMPUS
VENTURE II SUITE 400
920 MAIN CAMPUS DRIVE
RALEIGH, NORTH CAROLINA 27606

TELEPHONE (919) 424-3710
FACSIMILE (919) 424-3711

March 18, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on 3/18/02

Shaylor E. Dunn
Shaylor E. Dunn

Date of Signature 3/18/02

U.S. Patent and Trademark Office
BOX SEQUENCE
P.O. Box 2327
Arlington, Virginia 22202

Re: U.S. Patent Application Serial No. 10/029,413 for PURIFIED AND ISOLATED PLATELET AND CALCIUM CHANNEL NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC AND SCREENING METHODS USING SAME
Our File No. 421/29/2

Sir:

Enclosed please find the following:

1. A Response to the Notice to File Missing Parts and Preliminary Amendment (3 pages);
2. An executed Declaration (2 pages);
3. A copy of the Notice to File Missing Parts (2 pages) and a copy of the Sequence Listing Error Report (13 pages);
4. Sequence Listing in Paper (154 pages) and Computer Readable Form;
5. A Statement that Sequence Listing and Computer Readable Copy are the same;
6. Seventeen (17) sheets of formal drawings;
7. A Transmittal of Formal Drawings;

Commissioner for Patents
March 18, 2002
Page 2


8. A check in the amount of \$1,065.00; and
9. A return-receipt postcard to be returned to our offices with the U.S. Patent and Trademark filing stamp thereon.

Please contact our offices if there are any questions with this matter.

Although a check is being submitted, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this correspondence to Deposit Account Number 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.



Arles A. Taylor, Jr.

Registration No. 39,395

Customer No. Bar Code Label:



25297

PATENT TRADEMARK OFFICE

AAT/JAL/sed

Enclosures



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on 3/18/02

Shaylor E. Dunn
Shaylor E. Dunn
Date of Signature 3/18/02

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Malouf et al.

Examiner: Not Assigned

Application No.: 10/029,413

Group Art Unit: Not Assigned

Filed: December 20, 2001

Docket No.: 421/29/2

Confirmation No.: 3695

For: PURIFIED AND ISOLATED PLATELET AND CALCIUM CHANNEL NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC AND SCREENING METHODS USING SAME

RESPONSE TO NOTICE TO FILE MISSING PARTS -- FILING DATE GRANTED AND PRELIMINARY AMENDMENT

U.S. Patent and Trademark Office
BOX SEQUENCE
P.O. Box 2327
Arlington, Virginia 22202

Sir:

Responsive to the "Notice to File Missing Parts of Nonprovisional Application-Filing Date Granted" dated January 31, 2002, and having a period for response set to expire on March 31, 2002, applicants respectfully submit the following.

AMENDMENTS

IN THE SPECIFICATION:

Please delete the sequence listing on pages 102-259 of the application as filed and insert in place thereof the sequence listing attached herewith.

REMARKS

A. Sequence Listing

The specification of the subject U.S. Patent Application has been amended by deleting the Sequence Listing as filed and inserting in place thereof the accompanying

substitute Sequence Listing. The contents of the enclosed substitute paper and the enclosed computer readable copies of the Sequence Listing are the same. Pursuant to 37 C.F.R. § 1.821, no new matter has been added. A copy of the Sequence Listing Error Report is also enclosed. Applicants submit that this Response with accompanying documents places the application in compliance with the rules governing nucleotide and/or amino acid sequence disclosure as set forth in the most current version of 37 C.F.R. §§ 1.821-1.825. Support for the Amendment to the specification is found in the originally filed paper copy of the Sequence Listing.

Summarily, the Sequence Listing has been updated to comply with 37 C.F.R. §1.823. The substitute paper copy of the Sequence Listing includes no new matter in accordance with 37 C.F.R. §§ 1.821-1.825. The content of the paper and the computer readable forms of the Sequence Listing is the same, as required by 37 C.F.R. §§ 1.821-1.825. A statement to this effect is also enclosed.

B. Fees Owed

The Notice states that a total fee of \$1,065.00 is owed. The Notice states that the following individual fees are owed: \$370.00 to cover the basic filing fee for a small entity; \$378.00 for 42 claims over 20; and \$252.00 for 6 independent claims over 3. A check for \$1,065.00 is enclosed herewith.

C. Unsigned Oath or Declaration

The Notice states that a signed oath or declaration is also required. A declaration signed by each co-inventor is enclosed herewith.

The Commissioner or his representative is invited to contact the undersigned for clarification of this correspondence as necessary.